DIRS.INFO The most relevant business & tech news

☆ Bladder cancer studies suggest new ways to treat the disease and improve survival
▼ + stars: | 2023-10-22 | by ( Jacqueline Howard | ) edition.cnn.com time to read: +9 min

This is one of several new studies exploring ways to improve how bladder cancer is treated. “Ever since I was in med school, a metastatic bladder cancer treatment was gemcitabine and platinum. Urothelial cancer is a type of bladder cancer that begins in the urothelial cells, which line the inside of the bladder. The drug became the first therapy targeting a genetic alteration to be approved by the FDA to treat patients with the most common type of bladder cancer, metastatic urothelial cancer. “These results support nivolumab plus cisplatin-based chemo as a new standard approach for the treatment of metastatic urothelial cancer.”

Persons: vedotin, hadn’t, ”, Thomas Powles, ” Powles, we’ve, —, Powles, Toni Choueiri, Dana, “, enfortumab, ” Choueiri, drugmaker Janssen, Dr, Sanjay Gupta, nivolumab, Matthew Galsky Organizations: CNN, Society for Medical Oncology, University of London, Barts Cancer, US, Inc, Astellas Pharma, Merck, Co, Food and Drug Administration, FDA, EMA, Lank, Genitourinary Oncology, Farber Cancer Institute, ESMO, New England, of Medicine, University of Texas, Anderson Cancer Center, US Food and Drug Administration, National Library of Medicine, CNN Health, Bristol Myers Squibb, Ono Pharmaceutical Company, Cancer, The Tisch Cancer Institute Locations: Madrid, United Kingdom, United States, Europe, Mount Sinai

☆ AstraZeneca shares fall as abstract for lung cancer trial data disappoints
▼ + stars: | 2023-10-18 | by ( ) www.reuters.com time to read: 1 min

A company logo is seen at the AstraZeneca site in Macclesfield, Britain, May 11, 2021. REUTERS/Phil Noble/File Photo Acquire Licensing RightsOct 18 (Reuters) - Shares in AstraZeneca (AZN.L) fell more than 4% on Wednesday after the publication of an abstract on its experimental precision drug's use in lung cancer in a late-stage trial disappointed some analysts. The abstract was published ahead the European Society for Medical Oncology's (ESMO) congress that kicks off in Madrid on Friday. By 1219 GMT, AstraZeneca shares were dwon 3.7% in London, while the broader STOXX Health Care (.SXDP)index was off 1%. Reporting by Danilo Masoni and Maggie FickOur Standards: The Thomson Reuters Trust Principles.

Persons: Phil Noble, Danilo Masoni, Maggie Fick Organizations: AstraZeneca, REUTERS, European Society for Medical, Thomson Locations: Macclesfield, Britain, Madrid, London

☆ AstraZeneca shares fall as lung cancer drug trial data abstract disappoints
▼ + stars: | 2023-10-18 | by ( ) www.reuters.com time to read: +2 min

REUTERS/Phil Noble/File Photo Acquire Licensing RightsOct 18 (Reuters) - Shares in AstraZeneca (AZN.L) fell more than 4% on Wednesday after a data abstract on its experimental precision drug's use in lung cancer patients in a late-stage trial disappointed some analysts. Fernandez added that progression-free survival in lung cancer patients came in below expectations. Barclays analyst Emily Field also said in a note that safety looked better than expected for lung cancer patients and the data abstracts were "collectively positive" for AstraZeneca. London-listed shares of AstraZeneca were down 3.7% at 1219 GMT, while the broader STOXX Health Care (.SXDP) index was off 1%. Shares of AstraZeneca's Japanese partner Daiichi Sankyo (4568.T), which is jointly developing the cancer drug, closed 4.6% lower on Tuesday.

Persons: Phil Noble, datopotamab deruxtecan, Jefferies, Stephen Barker, Barker, Seamus Fernandez, Fernandez, Emily Field, GSK's, Danilo Masoni, Maggie Fick, Bhanvi, Shinjini Organizations: AstraZeneca, REUTERS, European Society for Medical, Friday, Guggeinheim, Barclays, AstraZeneca ., Thomson Locations: Macclesfield, Britain, Madrid, AstraZeneca . London, U.S, Milan, London, Bengaluru

An experimental treatment for advanced melanoma is poised to be the next major advance in cancer treatment, experts say. Those who got TIL therapy had a 50% reduction in disease progression and death, compared to those who were treated with ipilimumab, the study found. Bruce Hawley and his wife, Laurie, celebrated their third wedding anniversary in 2021 in Vancouver, several years after his TIL therapy. "The chemotherapy knocks down the immune cells to make space for the TIL cells going in," Hwu said. The hope is that TIL therapy will also be used for other solid cancers, not just melanoma, Rosenberg said.

☆ Cancer death rates continue to fall, driven by new treatments and improved screening
▼ + stars: | 2022-09-21 | by ( Kaitlin Sullivan | Kaitlin Sullivan Is A Contributor For Nbcnews.Com Who Has Worked With Nbc News Investigations. She Reports On Health | Science | ) www.nbcnews.com time to read: +6 min

Significant strides in cancer treatments, diagnostic tools and prevention strategies continue to drive down cancer death rates, according to a report published Wednesday by the American Association for Cancer Research. Death rates from cancer have been falling over the past two decades, particularly sharply in recent years, the group's annual Cancer Progress Report found. “Cancer cells are mavericks, but they are your own cells. Coussens also highlighted developments in cancer drugs that work by targeting specific DNA mutations in cancer cells but noted that more work is still needed. Catching cancer earlyAlso key to cutting cancer death rates is catching the disease as early as possible.

☆ Tratamentul modern al cancerului mamar – mastectomie cu reconstrucția sânului într-o singură intervenție
▼ + stars: | 2021-03-18 | by ( ) www.jurnal.md time to read: +5 min

Sursa foto: medpark.mdTratamentul modern al cancerului mamar – mastectomie cu reconstrucția sânului într-o singură intervențieEchipa mixtă de chirurgi mamologi și plasticieni Medpark a efectuat în premieră o mastectomie (înlăturarea sânului) cu biopsia ganglionului limfatic santinelă și reconstrucție mamară într-o singură intervenție. De aceea, posibilitatea reconstrucției imediate a sânului se ia în calcul încă de la etapa de planificare a intervenției la Medpark. Toate studiile știintifice au demonstrat că reconstrucția sânului nu influențează riscul de recidivă locală. Reconstrucția sânului imediată după mastectomie îmbunătățește semnificativ calitatea vieții femeilor, reducând substanțial impactul psihologic negativ dat de pierderea sânului.”Alte avantaje ale intervenției combinate sunt:O singură administrare de anestezie. După intervenție pacienta este monitorizată, efectuează investigații postoperatorii, pansamente și tot acest proces va avea loc o singură dată.

Persons: Medpark, Biopsia, Dragomir Tîmbur, Iulian Balan, Galina, Anesteziologia Locations: mastectomie

☆ Tot ce trebuie să știi despre cancerul de col uterin: Interviu cu dr. Lilian Guțu, chirurg ginecolog-oncolog
▼ + stars: | 2020-12-10 | by ( ) www.jurnal.md time to read: +7 min

Cât de eficiente sunt screeningul și vaccinarea în cancerul de col uterin? Screeningul cancerului de col uterin este un element foarte important al sistemului de sănătate în orice stat care își dorește să lupte cu această problemă. Soluția este ca orice femeie, fiind informată și sensibilizată despre problema cancerului de col uterin, să efectueze controale regulate la medicul ginecolog. Jurnal.mdCe semne trebuie să alerteze femeia privind posibila prezență a cancerului de col uterin? În cazul în care cancerul a afectat țesuturile adiacente / ganglionii limfatici, chirurgia cu limfodisecție este obligatorie.

Persons: Babeș Locations: Australia, Canada

Search resuls for: "ESMO"

7 mentions found